MA30992B1 - Compositions de dihydrochlorure d'azimilide - Google Patents

Compositions de dihydrochlorure d'azimilide

Info

Publication number
MA30992B1
MA30992B1 MA31991A MA31991A MA30992B1 MA 30992 B1 MA30992 B1 MA 30992B1 MA 31991 A MA31991 A MA 31991A MA 31991 A MA31991 A MA 31991A MA 30992 B1 MA30992 B1 MA 30992B1
Authority
MA
Morocco
Prior art keywords
compositions
dihydrochloride
azimilide dihydrochloride
azimilide
imidazolidinedione
Prior art date
Application number
MA31991A
Other languages
English (en)
Inventor
Nancy Lee Redman-Furey
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA30992B1 publication Critical patent/MA30992B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES SOLVATES ET DES FORMES POLYMORPHES VARIÉES DE DIHYDROCHLORURE DE (E)- 1-[[[5-(4-CHLOROPHÉNYL)-2-FURANYL]MÉTHYLÈNE]AMINO]-3-[4-(4-MÉTHYL-1-PIPÉRAZINYL)BUTYL]-2,4- IMIDAZOLIDINEDIONE ET DES COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI.
MA31991A 2006-12-15 2009-06-15 Compositions de dihydrochlorure d'azimilide MA30992B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87505106P 2006-12-15 2006-12-15

Publications (1)

Publication Number Publication Date
MA30992B1 true MA30992B1 (fr) 2009-12-01

Family

ID=39401118

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31991A MA30992B1 (fr) 2006-12-15 2009-06-15 Compositions de dihydrochlorure d'azimilide

Country Status (19)

Country Link
US (2) US20080182858A1 (fr)
EP (1) EP2125791A2 (fr)
JP (1) JP2010513264A (fr)
KR (1) KR20090089416A (fr)
CN (1) CN101558063A (fr)
AR (1) AR064367A1 (fr)
AU (1) AU2007331033A1 (fr)
BR (1) BRPI0720265A2 (fr)
CA (1) CA2672132A1 (fr)
CL (1) CL2007003643A1 (fr)
IL (1) IL198807A0 (fr)
MA (1) MA30992B1 (fr)
MX (1) MX2009006475A (fr)
PE (1) PE20081481A1 (fr)
RU (1) RU2009117558A (fr)
SM (1) SMAP200900061A (fr)
TW (1) TW200840578A (fr)
WO (1) WO2008072190A2 (fr)
ZA (1) ZA200903390B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552602B1 (fr) 2009-03-18 2025-03-05 Incarda Therapeutics, Inc. Unité de doses, aérosols, kits et procédés pour le traitement de maladies cardiaques par administration pulmonaire
AU2016256776B2 (en) * 2009-03-18 2018-04-12 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) * 2009-03-18 2016-08-18 Incarda Therapeutics, Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CN101735203B (zh) * 2009-12-17 2012-05-23 天津药物研究院 盐酸阿齐利特的晶型ⅱ及其制备方法和用途
EP3380152B1 (fr) * 2015-11-27 2020-10-28 Sanofi-Aventis Deutschland GmbH Dispositif d'injection de médicament
CN109069495A (zh) 2016-02-01 2018-12-21 英凯达治疗公司 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
AU2020323594B2 (en) 2019-08-01 2022-02-03 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN113861164B (zh) * 2021-10-29 2022-09-20 迪嘉药业集团有限公司 一种烟碱的结晶制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
SK282656B6 (sk) * 1991-08-14 2002-11-06 Procter And Gamble Pharmaceuticals 4-Oxocyklická zlúčenina močoviny použiteľná ako antiarytmické a antifibrilačné činidlo a farmaceutický prostriedok s jej obsahom
ATE275563T1 (de) * 1998-04-29 2004-09-15 Procter & Gamble Verfahren zur herstellung von 1,3- disubstituierten-4-oxocyclischen harnstoffen
SK15842000A3 (sk) * 1998-04-29 2001-06-11 The Procter & Gamble Company Spôsob prípravy 1,3-disubstituovaných-4-oxocyklických močovín
EP1622875B1 (fr) * 2003-05-08 2009-12-02 Theravance, Inc. Formes cristallines d'un agoniste arylaniline du récepteur adrénergique bêta-2

Also Published As

Publication number Publication date
AU2007331033A1 (en) 2008-06-19
CL2007003643A1 (es) 2008-03-24
TW200840578A (en) 2008-10-16
IL198807A0 (en) 2010-02-17
CA2672132A1 (fr) 2008-06-19
RU2009117558A (ru) 2011-01-20
PE20081481A1 (es) 2008-11-07
WO2008072190A3 (fr) 2008-11-06
KR20090089416A (ko) 2009-08-21
CN101558063A (zh) 2009-10-14
MX2009006475A (es) 2009-06-26
WO2008072190A2 (fr) 2008-06-19
SMAP200900061A (it) 2009-09-07
AR064367A1 (es) 2009-04-01
JP2010513264A (ja) 2010-04-30
EP2125791A2 (fr) 2009-12-02
ZA200903390B (en) 2010-04-28
US20080182858A1 (en) 2008-07-31
BRPI0720265A2 (pt) 2014-01-28
US20110237603A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
MA30992B1 (fr) Compositions de dihydrochlorure d'azimilide
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
EP1954683A4 (fr) 2-(phenyl ou heterocyclique)-1h-phenantrho(9,10-d)imidazoles utilisees comme inhibiteurs de la mpges-1
ATE299494T1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
AR112118A2 (es) Inhibidores de pi-3 quinasa
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
NO20090834L (no) Anvendelse av azabicykloheksanderivater
WO2006054143A8 (fr) Formes polymorphes de {5-[3-(4,6-difluoro-1h-benzimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
WO2008027542A3 (fr) Composés d'isoindoline substituée en 5
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
CL2010001608A1 (es) Compuestos derivados de 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-4,5-dihidro-2h-isoquinolin-1-ona y 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-3,4-dihidro-2h-isoquinolin-1-ona, inhibidores de quinasa; composicion farmaceutica; utiles en el tratamiento de estados patologicos inflamatorios y/o inmunes.
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
WO2006034093A3 (fr) Inhibiteurs de bace
NO20091052L (no) Diaryleterderivater og anvendelser derav
PL1863477T3 (pl) 3,4-Podstawione pochodne pirolidyny do leczenia nadciśnienia
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
WO2007016087A3 (fr) Antagonistes des récepteurs de cgrp de benzodiazépine hétérocyclique
DE602006006536D1 (de) Trockene Aripiprazolformulierungen
WO2008013823A3 (fr) Co-cristaux de (2r-trans)-6-chloro-5-[[4-[(4-fluorophényl)méthyl]-2,5-diméthyl-1-pipérazinyl]carbonyl]-n,n,1-triméthyl-alpha-oxo-1h-indole-3-acétamide
MXPA03006958A (es) Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.